

Title (en)
((1S,9S)-11-[[4-(1,3-BENZODIOXOL-5-YLAMINO)-8-METHYL-2-QUINAZOLINYL]METHYL]-7,11-DIAZATRICYCLO[7.3.1.0~2,7~]TRIDECA-2,4-DIEN-6-ONE) AS A STABILIZER OF CRY5 FOR THE TREATMENT OF CIRCADIAN RHYTHM ASSOCIATED DISEASES AND DISORDERS

Title (de)
((1S,9S)-11-[[4-(1,3-BENZODIOXOL-5-YLAMINO)-8-METHYL-2-QUINAZOLINYL]METHYL]-7,11-DIAZATRICYCLO[7.1.0!-2,4-TRIDECA-2,4-DIEN-6-ON ZUR BEHANDLUNG VON ZIRKADIANEN RHYTHMUSSTÖRUNGEN

Title (fr)
((1S,9S)-11-[[4-(1,3-BENZODIOXOL-5-YLAMINO)-8-MÉTHYL-2-QUINAZOLINYL]MÉTHYL]-7,11-DIAZATRICYCLO[7.3.1.0~2,7~]TRIDECA-2,4-DIÈN-6-ONE) EN TANT QUE STABILISANT DE CRY5 POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES ASSOCIÉS AU RYTHME CIRCADIEN

Publication
EP 4346833 A1 20240410 (EN)

Application
EP 21736769 A 20210531

Priority
TR 2021050513 W 20210531

Abstract (en)
[origin: WO2022255955A1] The present invention relates to ((1S,9S)-11-[[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quinazolinyl]methyl]-7,11-diazatricyclo[7.3.1.0~2,7~] trideca-2,4-dien-6-one) compound and related derivatives. The compound of the invention is a CRY1/2-binding small molecule and also a stabilizer of CRY1 and CRY2 proteins, and is therefore useful, as pharmaceutical agent, especially in the treatment and/or prevention of disorders associated with the circadian rhythm, including CRY1-mediated diseases such as diabetes.

IPC 8 full level
A61K 31/517 (2006.01); **A61P 3/10** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)
A61K 31/517 (2013.01); **A61P 3/10** (2018.01); **A61P 43/00** (2018.01)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
KH MA MD TN

DOCDB simple family (publication)
WO 2022255955 A1 20221208; EP 4346833 A1 20240410

DOCDB simple family (application)
TR 2021050513 W 20210531; EP 21736769 A 20210531